ASB Consultores LLC Sells 1,331 Shares of Danaher Co. (NYSE:DHR)

ASB Consultores LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 30.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,031 shares of the conglomerate’s stock after selling 1,331 shares during the period. ASB Consultores LLC’s holdings in Danaher were worth $757,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new position in Danaher during the 4th quarter worth $25,000. Tsfg LLC increased its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher during the 2nd quarter worth $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the 2nd quarter worth $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter worth $30,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on DHR. Jefferies Financial Group began coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Leerink Partners increased their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group increased their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Performance

Shares of DHR stock opened at $276.43 on Friday. The business’s 50-day moving average price is $267.10 and its 200-day moving average price is $257.03. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The firm has a market capitalization of $204.75 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 4.48 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the firm posted $2.05 earnings per share. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of the stock is owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.